Skip to main content
< Back to news
Carme Plasencia, cofounder and CEO of Aromics, receiving the award (Photo: SIWHT).

The biotechnology company Aromics has been recognized as one of the most innovative Biotecs at the Sino-Europe Healthtech Innovation Week in China

The Horizon 2020 project BERMES aimed to develop a novel therapy for malignant mesothelioma, lead by the catalan biotech company Aromics, was recognized as one of the most innovative initiatives at the Sino-Europe Innovation Week of Health Technology which was held from 12th to 16th October at two of the most technological and powerful cities in China: Nanjing and Shanghai. The biotechnology company, located at the Barcelona Science Park, participated in the event as part of a mission organized by the BioRegion of Catalonia to explore new opportunities for collaboration with Chinese companies and institutions and to learn about the experience of other European clusters in the Asian giant.


Biocat, based in the Barcelona Science Park, participated this October for the first time in the Sino-Europe Innovation Week of Health Technology (SIWHT 2019) in China, coordinating a mission of the BioRegion, made up of the companies Aromics , Avida Biotech and Goodger , together with the company Smart Bcn Technologies, of Catalan origin and based in Malaysia.

SIWHT aims to establish communication platforms between European entrepreneurs and Chinese investors in life sciences to integrate into the innovation ecosystem and the Chinese market. The Catalan mission program included a roadshow through two of China’s most powerful technological cities: Shanghai and Nanjing, during which participating companies were able to present their projects and hold individual meetings with potential Asian investors.

The meeting in Nanjing was attended by important representatives of the main economic and diplomatic institutions of the region’s government and the participating European clusters, who coincided in the driving role of this life sciences hub in China, formed by an axis that also includes the city of Suzhou and its industrial park. The mission also included a visit to some of the most important health incubators in the region.

The event concluded with the presentation of awards to European companies with the most innovative initiatives. Aromics was awarded the 3rd prize in the category “SINO-EU Medical Innovation Project”.

Aromics is an innovative SME that, from its headquarters in the Barcelona Science Park, works in the application of the OMIC sciences in the search and development of new therapeutic compounds. The most advanced project in its portfolio is BERMES, whose objective is to complete the pre-clinical regulatory stage of NAX035, an innovative treatment for malignant mesothelioma, a very aggressive cancer directly related to asbestos exposure.

“This congress has given us the opportunity to explore the possibilities of a product such as ours in a new market with a large volume such as China. The project has been very well received and now we must explore the contacts initiated with the different actors including investors and potential collaborators”, explains Carmen Plasencia, co-founder and CEO of Aromics Biotech.

Related news [+]